Trial of Modifications to Radical Prostatectomy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01407263 |
Recruitment Status :
Recruiting
First Posted : August 2, 2011
Last Update Posted : March 21, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer | Procedure: Lymph node template Procedure: Transverse versus vertical closure Drug: antibiotic prophylaxis | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 2600 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Trial of Modifications to Radical Prostatectomy |
Study Start Date : | July 2011 |
Estimated Primary Completion Date : | July 2023 |
Estimated Study Completion Date : | July 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Lymphadenectomy vs. no lymphadenectomy
In patients randomized to standard, only the nodal packet under the external iliac vein and above the obturator nerve will be dissected. For patients randomized to the modified template, the external iliac, hypogastric and obturator fossa nodal groups will be removed.No lymph nodes will be removed in patients randomized to the no PLND arm.
|
Procedure: Lymph node template
Inclusion of the external iliac, hypogastric and obturator fossa nodal groups in the template undergoing a Radical Prostatectomy. Modifying the template for lymph node dissection may lead to removal of additional affected nodes, reducing the chance of recurrence. .No lymph nodes will be removed in patients randomized to the no PLND arm. |
Experimental: Transverse versus vertical closure of the port site incision (Closed as of 9/30/2021) |
Procedure: Transverse versus vertical closure
Transverse versus vertical closure of the port site incision |
Experimental: One vs. three days of antibiotic prophylaxis (Closed as of 9/30/2021) |
Drug: antibiotic prophylaxis
One vs. three days of antibiotic prophylaxis at catheter removal |
- Patient-reported hernia [ Time Frame: 1 year ]Patient-reported hernia is a routine assessment on post-operative questionnaires completed by prostate cancer patients at MSKCC. The questionnaire asks about hernia near the surgical scar and if there has been a need for surgical repair of the hernia.
- To evaluate whether a modification to the template for lymph node dissection reduces biochemical recurrence rates [ Time Frame: 2 years ]Biochemical recurrence is defined as any postoperative PSA of 0.2 ng / mL or higher, or treatment with hormones, radiotherapy or chemotherapy starting six months or more after radical prostatectomy.
- urinary tract infection (UTI) [ Time Frame: within 10 days ]urinary tract infection (UTI) within 10 days of catheter removal. We will use the CDC's definition of UTI: symptomatic UTI diagnosed in patients with positive urine cultures (≥100,000 microorganisms per cm3) and at least one of the following signs or symptoms with no other recognized cause: fever (>38oC), urgency, frequency, dysuria or suprapubic tenderness.50 UTI is routinely captured by clinical staff as a surgical complication.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients do not have to be eligible for both modifications to be included in the study.
Lymphadenectomy vs no lymphadenectomy:
- Patients 21 years or older scheduled for radical prostatectomy for treatment of prostate cancer with one of the consenting surgeons at MSKCC
Exclusion Criteria:
Lymphadenectomy vs no lymphadenectomy
- Presence of positive/suspicious pelvic nodes on MRI, CT or PSMA scan (positive/suspicious defined as a pelvic node >15mm in short axis or a node with abnormal morphology such as roundness or irregularity or loss of fatty hilum
- Any prior pelvic radiation therapy used to treat prostate cancer

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01407263
Contact: Andrew Vickers, PhD | 646-888-8233 | ||
Contact: Peter Scardino, MD | 646-422-4329 |
United States, New Jersey | |
Memorial Sloan Kettering Cancer Center at Basking Ridge | Recruiting |
Basking Ridge, New Jersey, United States, 07920 | |
Contact: Andrew Vickers, PhD 646-888-8233 | |
United States, New York | |
Memorial Sloan Kettering Westchester | Recruiting |
Harrison, New York, United States, 10604 | |
Contact: Andrew Vickers, PhD 646-888-8233 | |
Memorial Sloan Kettering Cancer Center | Recruiting |
New York, New York, United States, 10065 | |
Contact: Andrew Vickers, PhD 646-888-8233 | |
Contact: Peter Scardino, MD 646-422-4329 | |
Principal Investigator: Andrew Vickers, PhD |
Principal Investigator: | Andrew Vickers, PhD | Memorial Sloan Kettering Cancer Center |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT01407263 |
Other Study ID Numbers: |
11-096 |
First Posted: | August 2, 2011 Key Record Dates |
Last Update Posted: | March 21, 2022 |
Last Verified: | March 2022 |
radical prostatectomy anastomotic suturing lymph node dissection 11-096 |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site |
Neoplasms Prostatic Diseases Anti-Bacterial Agents Anti-Infective Agents |